Second Amendment to Chromocell Therapeutics Corporation 2023 Equity Incentive Plan

Contract Categories: Human Resources › Bonus & Incentive Agreements
Summary

This amendment, effective June 12, 2024, modifies the Chromocell Therapeutics Corporation 2023 Equity Incentive Plan by reducing the number of shares available under the plan from 4,000,000 to 1,944,444. All other terms and conditions of the original plan remain unchanged. The amendment was adopted by the company's Board of Directors.

View More
EX-10.1 2 g084536_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

SECOND AMENDMENT TO THE CHROMOCELL THERAPEUTICS CORPORATION

2023 EQUITY INCENTIVE PLAN

 

 

 

As adopted by resolution of the

Board of Directors effective as of June 12, 2024

 

 

 

1.            Section 3 of the Chromocell Therapeutics Corporation 2023 Equity Incentive Plan (the “2023 Plan”) is amended by deleting the number “4,000,000” and inserting therefor “1,944,444”.

 

2.            Except as hereinabove amended, the provisions of the 2023 Plan shall remain in full force and effect.